Sugi Predict

Sugi Predict / Compounds / SCHEMBL4876509

SCHEMBL4876509

SCHEMBL4876509

NC(CO)c1ccc(F)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.43
▸ CES1 P23141 2/20 0.43
▸ IDO1 P14902 3/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ CYP3A4 P08684 2/20 0.40
▸ SLC6A2 P23975 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ AGXT P21549 2/20 0.37
▸ DPP4 P27487 2/20 0.37
▸ CA3 P07451 1/20 0.35
▸ CA6 P23280 1/20 0.35
▸ CA5A P35218 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ CA5B Q9Y2D0 1/20 0.35
▸ PDE2A O00408 1/20 0.34
▸ PSEN1 P49768 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513268 1.00 CES2 (0.43) CES2CES1IDO1TDO2CYP3A4
Hydrochloric Acid SCHEMBL1440966 0.98 IDO1 (0.44) CES2CES1IDO1TDO2CYP3A4
Hydrochloric Acid SCHEMBL1440962 0.98 IDO1 (0.44) CES2CES1IDO1TDO2CYP3A4
SCHEMBL3382884 0.85 CES2 (0.41) CES2CES1IDO1TDO2CYP3A4
SCHEMBL3383601 0.85 CES2 (0.41) CES2CES1IDO1TDO2CYP3A4
SCHEMBL3382882 0.85 CES2 (0.41) CES2CES1IDO1TDO2CYP3A4
SCHEMBL8514443 0.84 PSEN1 (0.43) CES2CES1IDO1ALDH1A1AGXT
SCHEMBL8514447 0.84 PSEN1 (0.43) CES2CES1IDO1ALDH1A1AGXT
SCHEMBL31047107 0.82 CA3 (0.43) CES2CES1CYP3A4DPP4CA3
SCHEMBL11657956 0.82 CYP3A4 (0.44) CES2CES1IDO1TDO2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2026-05-07 — — US disclosed
US-12370194-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2025-07-29 — — US disclosed
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2024-09-19 — — US disclosed
US-11938134-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
US-20220088018-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2022-03-24 — — US disclosed
US-11149040-B2 Fused triazole agonists of the APJ receptor AMGEN INC. (US) 2021-10-19 — — US disclosed
US-20200308189-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2020-10-01 — — US disclosed
EP-3704122-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR Amgen Inc. (US) 2020-09-09 — — EP disclosed
US-20200171028-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS HOLDINGS, LLC 2020-06-04 — — US disclosed
US-20200171028-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS HOLDINGS, LLC 2020-06-04 — — US disclosed
EP-2643313-B9 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2017-02-22 — — EP disclosed
EP-2643313-B1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2016-06-29 — — EP disclosed
US-8946247-B2 Quinazoline carboxamide azetidines MERCK PATENT GMBH (DE) 2015-02-03 — — US disclosed
EP-2643313-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES Merck Patent GmbH (DE) 2013-10-02 — — EP disclosed
US-20130252942-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2013-09-26 — — US disclosed
WO-2012069146-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2012-05-31 — — WO disclosed
US-7326786-B2 Thiazolinone unsubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2008-02-05 — — US disclosed
EP-1765817-A1 THIAZOLINONE UNSUBSTITUTED QUINOLINES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-28 — — EP disclosed
WO-2006002829-A1 THIAZOLINONE UNSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-01-12 — — WO disclosed
US-20060004045-A1 Thiazolinone unsubstituted quinolines CHEN LI 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308189-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AP3M1, GPBAR1 CES2 3986/4885CES1 2734/4885IDO1 3866/4885
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC1, HDAC2 CES2 1096/4885CES1 699/4885IDO1 2471/4885
US-20220088018-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC1, HDAC2 CES2 1096/4885CES1 699/4885IDO1 2471/4885
US-20200171028-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC1, HDAC2 CES2 1096/4885CES1 699/4885IDO1 2471/4885
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC3, HDAC1 CES2 161/4885CES1 201/4885IDO1 2887/4885
US-11938134-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 CES2 1096/4885CES1 699/4885IDO1 2471/4885
US-20130252942-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES AZI2, NQO2, ABL1 CES2 1988/4885CES1 1214/4885IDO1 231/4885
US-11149040-B2 Fused triazole agonists of the APJ receptor TBXA2R, AP3M1, GPBAR1 CES2 3986/4885CES1 2734/4885IDO1 3866/4885
US-20060004045-A1 Thiazolinone unsubstituted quinolines CDK1, CDK17, CDK14 CES2 4505/4885CES1 3675/4885IDO1 2185/4885
US-12370194-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 CES2 1096/4885CES1 699/4885IDO1 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.